Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.

Abstract: Disclosed herein is a nanocomposite comprising a core-shell nanoparticle and a core-shell quantum dot. The core-shell nanoparticle comprises a phosphor core, a shell layer, and a cleavable peptide. The core-shell quantum dot comprises a center core, an intermediate layer, an outer layer, a silica layer, and an arginylglycylaspartic acid (RGD) peptide. The core-shell nanoparticle and the core-shell quantum dot are linked to each other via forming a peptide bond between the cleavable peptide and the RGD peptide. Also disclosed are the uses of the nanocomposite in making a diagnosis of tumors.

Abstract: Disclosed herein is a micro-reactor for synthesizing a molecule, for example, compound, a nanoparticle, or a quantum dot. According to embodiments of the present disclosure, the apparatus comprises a processor, a storage unit, a reaction unit, a detector, and a collector, in which the storage unit and the reaction unit are independently controlled by the process. Optionally, the present micro-reactor further comprises a diagnostic device for performing a diagnostic test on a biological sample by use of the molecule. Also disclosed wherein are methods of diagnosing and treating a disease in a subject with the aid of the present micro-reactor.

Abstract: Disclosed herein is a micro-reactor for synthesizing a molecule, for example, compound, a nanoparticle, or a quantum dot. According to embodiments of the present disclosure, the apparatus comprises a processor, a storage unit, a reaction unit, a detector, and a collector, in which the storage unit and the reaction unit are independently controlled by the process. Optionally, the present micro-reactor further comprises a diagnostic device for performing a diagnostic test on a biological sample by use of the molecule. Also disclosed wherein are methods of diagnosing and treating a disease in a subject with the aid of the present micro-reactor.

Abstract: Disclosed herein is a nanocomposite particle comprising a core-shell-shell nanoparticle, an encapsulated nanorod linked with the core-shell-shell nanoparticle, and a lipid layer encapsulating the core-shell-shell nanoparticle and the encapsulated nanorod. The core-shell nanoparticle comprises a phosphor core, an inner shell layer, an outer shell layer, and a cationic polymer. The encapsulated nanorod comprises a nanorod, and a mesoporous scaffold. According to embodiments of the present disclosure, the encapsulated nanorod is linked with the core-shell-shell nanoparticle via an electrostatic interaction between the cationic polymer and the mesoporous scaffold. Also disclosed are the uses of the nanocomposite in treating diseases, for example, cancers.

Abstract: Disclosed herein is a nanocomposite comprising a core-shell nanoparticle and a core-shell quantum dot. The core-shell nanoparticle comprises a phosphor core, a shell layer, and a cleavable peptide. The core-shell quantum dot comprises a center core, an intermediate layer, an outer layer, a silica layer, and an arginylglycylaspartic acid (RGD) peptide. The core-shell nanoparticle and the core-shell quantum dot are linked to each other via forming a peptide bond between the cleavable peptide and the RGD peptide. Also disclosed are the uses of the nanocomposite in making a diagnosis of tumors.

Abstract: Disclosed herein is a method of enhancing the accuracy and/or sensitivity of ultrasound imaging in detecting a tumor in a subject. The method comprises administering to the subject an effective amount of a nanoparticle prior to the application of ultrasound to the subject. According to certain embodiments of the present disclosure, the nanoparticle is a magnetic nanoparticle, for example, a gold, silver, or iron oxide nanoparticle. Also disclosed herein are methods of treating a tumor in a subject by detecting the tumor via ultrasound with the aid of a nanoparticle, and then administering to the subject an anti-cancer treatment based on the location of the tumor revealed by the ultrasound image.

Abstract: Disclosed herein is an immunoconjugate comprising an antibody, a functional motif, and a linker connecting the functional motif to the antibody. According to embodiments of the present disclosure, the antibody may recognize tumor-associated antigens (TAAs), and serves as a targeting module for delivering the functional motif connected therewith to the tumor cells thereby inhibiting tumor growth or detecting the distribution of tumor cells. Also disclosed herein are methods of treating cancers and methods of diagnosing cancers by use of the present immunoconjugate.

Abstract: Disclosed herein is an immunoconjugate comprising an antibody, a functional motif, and a linker connecting the functional motif to the antibody. According to embodiments of the present disclosure, the antibody may recognize tumor-associated antigens (TAAs), and serves as a targeting module for delivering the functional motif connected therewith to the tumor cells thereby inhibiting tumor growth or detecting the distribution of tumor cells. Also disclosed herein are methods of treating cancers and methods of diagnosing cancers by use of the present immunoconjugate.

Abstract: Methods for reducing the growth of breast cancer cells in a subject by exposing the cells to nanoparticles, and irradiating with a focused, low to medium power ultrasound. The nanoparticles can be gold or magnetic nanoparticles. The nanoparticles can have a cancer drug attached, such as an antibody-based cancer drug.

Abstract: Methods for diagnosis of non-small cell lung cancers by detection of endogenous peptides in exhaled breath condensate (EBC) are provided. Diagnostic peptides derived from dermcidin (DC) are provided. A specific dermcidin-derived peptide E-R11, having the sequence ENAGEDPGLAR (SEQ ID NO:2), is provided. E-R11 peptide levels in EBC, as measured by mass spectrometry (MS), are highly diagnostic of non-small cell lung cancers. A method for inhibiting growth of lung cancer cells by inhibiting DCD expression by RNA interference also is provided.

Abstract: Methods for reducing the growth of breast cancer cells in a subject by exposing the cells to nanoparticles, and irradiating with a focused, low to medium power ultrasound. The nanoparticles can be gold or magnetic nanoparticles. The nanoparticles can have a cancer drug attached, such as an antibody-based cancer drug.

Abstract: Methods for killing cancer cells and treating cancer in a subject by exposing the cells to nanoparticles, and irradiating with a focused, low to medium power ultrasound. The nanoparticles can be gold, iron oxide, copper, silver, polystyrene, PEG, or liposome nanoparticles. The nanoparticles can have a cancer drug attached, such as an antibody-based cancer drug.

Abstract: Methods for killing cancer cells and treating cancer in a subject by exposing the cells to nanoparticles, and irradiating with a focused, low to medium power ultrasound. The nanoparticles can be gold, iron oxide, copper, silver, polystyrene, PEG, or liposome nanoparticles. The nanoparticles can have a cancer drug attached, such as an antibody-based cancer drug.

Abstract: Methods for diagnosis of non-small cell lung cancers by detection of endogenous peptides in exhaled breath condensate (EBC) are provided. Diagnostic peptides derived from dermcidin (DCD) are provided. A specific dermcidin-derived peptide E-R11, having the sequence ENAGEDPGLAR, is provided. E-R11 peptide levels in EBC, as measured by mass spectrometry (MS), are highly diagnostic of non-small cell lung cancers. A method for inhibiting growth of lung cancer cells by inhibiting DCD expression by RNA interference also is provided.

Abstract: An all solutions automatic test pattern generation (ATPG) engine method uses a decision selection heuristic that makes use of the “connectivity of gates” in the circuit in order to obtain a compact solution-set. The “symmetry in search-states” is analyzed using a “Success-Driven Learning” technique which is extended to prune conflict sub-spaces. A metric is used to determine the use of learnt information a priori, which information is stored and used efficiently during “success driven learning”.

Abstract: An integrated circuit with programmable transistors is programmed via a state machine on the integrated circuit. For example, the integrated circuit may be a programmable logic device, and the state machine may be a JTAG state machine. Each integrated circuit may have on it a register containing data indicating how long a particular programming operation should continue in order to be successful for that circuit. External programming control apparatus first reads that data and then at least partly bases the timing of programming instructions applied to the integrated circuit on that data. The integrated circuit may have an on-board programming voltage generating circuit which is turned on only by appropriate instructions from the external programming control apparatus. The external programming control apparatus controls the sequence and timing of all programming operations via the state machine port of the integrated circuit.